Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients
Camille N. Kotton
Abstract
On 8 December 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZeneca's Evusheld (tixagevimab copackaged with cilgavimab, administered as concomitant injections) for the prevention of COVID-19 in those who are moderately to severely compromised, are aged 12 years or older, and weigh more than 40 kg. This commentary discusses current appropriate use of this important preventive intervention.
Topics & Concepts
MedicineVirologyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyOutbreakPathologyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy